{
  "outcomes_metadata": {
    "timestamp": "2025-10-01T13:43:52.417476",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "consolidation_type": "outcomes",
    "data_split": "test",
    "total_unique_outcomes": 59,
    "source_countries": [
      "DE",
      "DK",
      "EN",
      "EU",
      "FR",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        "overall survival (OS)",
        "overall survival (time from randomisation to death from any cause)",
        "prolonged survival",
        "event-free survival",
        "eventless survival",
        "progression-free survival (PFS)",
        "progression-free survival (blinded independent central review)",
        "progression-free survival (RECIST v1.1)",
        "progression-free survival (PFS; RECIST 1.1)",
        "progression-free survival (independent review panel, RECIST 1.1)",
        "progression-free survival (sensitivity analysis including new anti-cancer therapy initiation as event)",
        "progression-free survival utility",
        "progression-free survival (measured by RECIST 1.1 criteria)",
        "health-related quality of life measured by time to death"
      ],
      "response_measures": [
        "objective response rate (ORR)",
        "objective response rate (ORR; RECIST 1.1; blinded independent central review)",
        "objective response rate (independent review panel, RECIST 1.1)",
        "objective response rate (RECIST 1.1 criteria)",
        "response rates",
        "complete response (RECIST 1.1)",
        "partial response (RECIST 1.1)",
        "disease control rate",
        "disease control rate (complete, partial, or stable disease for at least 5 weeks)",
        "duration of response (DoR)",
        "duration of response (RECIST 1.1)",
        "time to response",
        "time to response (from treatment initiation to first complete or partial response)",
        "treatment duration",
        "duration of treatment"
      ],
      "progression_measures": [
        "time to progression (TTP)",
        "time to progression",
        "time to next treatment (TTNT)",
        "time to next treatment",
        "dropout rate"
      ]
    },
    "safety": {
      "adverse_events": [
        "adverse events (total)",
        "adverse events",
        "adverse events (CTCAE v5.0)",
        "adverse events (CTCAE v4.03)",
        "adverse events (general)",
        "adverse events (general; CTCAE v5.0)",
        "adverse effects",
        "side effects (PRO-CTCAE instrument)",
        "grade 3 or higher adverse events",
        "grade 3-4 adverse event rate",
        "serious adverse events (SAEs)",
        "serious adverse events",
        "severe adverse events",
        "mortality-related toxicity",
        "discontinuation due to adverse events",
        "treatment discontinuation due to adverse events",
        "interstitial lung disease (severe adverse event)",
        "liver disorders (severe adverse event)",
        "stomatitis (adverse event)",
        "peripheral oedema (adverse event)",
        "peripheral neuropathy (adverse event)",
        "alopecia (adverse event)",
        "blood and lymphatic system disorders (adverse event)",
        "fatigue (adverse event)",
        "fatigue",
        "fever (adverse event)",
        "fever",
        "infections and infestations (adverse event)",
        "diarrhoea",
        "alanine aminotransferase increase",
        "aspartate aminotransferase increase",
        "neutropenia",
        "febrile neutropenia",
        "serious side effects on the skin"
      ],
      "serious_events": [
        "serious adverse events (SAEs)",
        "serious adverse events",
        "severe adverse events",
        "mortality-related toxicity",
        "interstitial lung disease (severe adverse event)",
        "liver disorders (severe adverse event)",
        "serious side effects on the skin"
      ],
      "discontinuations": [
        "discontinuation due to adverse events",
        "treatment discontinuation due to adverse events",
        "dropout rate"
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        "EORTC QLQ-C30",
        "EORTC QLQ-LC13",
        "EQ-5D visual analogue scale",
        "EQ-5D-5L",
        "NSCLC-SAQ",
        "BPI-SF",
        "FACT-G GP5",
        "FACT-G (item GP5)",
        "PGI-C",
        "PGIC",
        "PRO-CTCAE",
        "visual analogue scale (progression-free health state)"
      ],
      "functional_status": [
        "Karnofsky performance status",
        "ECOG performance status",
        "physical functioning"
      ],
      "symptom_measures": [
        "symptomatology (EORTC QLQ-C30)",
        "symptomatology (EORTC QLQ-LC13)",
        "symptom control",
        "changes in cancer-specific symptoms",
        "changes in overall health status",
        "physical benefits",
        "psychological benefits",
        "preservation of quality of life"
      ]
    },
    "economic": {
      "cost_effectiveness": [
        "cost-effectiveness (incremental cost-effectiveness ratio, ICER)",
        "cost-effectiveness (cost per QALY)"
      ],
      "utilities": [
        "quality-adjusted life years (QALYs)",
        "utility decrement per cycle of treatment",
        "health-state utility"
      ],
      "resource_utilization": []
    },
    "other": {
      "exploratory_endpoints": [],
      "biomarkers": []
    }
  }
}